Cirrhosis is an important cause of morbidity and mortality in people with chronic liver
disease worldwide. In 2019, cirrhosis was associated with 2.4% of global deaths. Owing to …

Non-alcoholic fatty liver disease (NAFLD) has become an epidemic, much like other non-
communicable diseases (NCDs), such as cancer, obesity, diabetes, and cardiovascular …

Nonalcoholic fatty liver disease (NAFLD) is an increasingly common condition that is
believed to affect> 25% of adults worldwide. Unless specific testing is done to identify …

Non-alcoholic fatty liver disease (NAFLD) is a potentially serious liver disease that affects
approximately one-quarter of the global adult population, causing a substantial burden of ill …

Ubiquitous yet unique, lipid droplets are intracellular organelles that are increasingly being
recognized for their versatility beyond energy storage. Advances uncovering the intricacies …

Non-alcoholic fatty liver disease (NAFLD) includes a range of hepatic manifestations,
starting with liver steatosis and potentially evolving towards non-alcoholic steatohepatitis …

Macrophages are important immune cells in innate immunity, and have remarkable
heterogeneity and polarization. Under pathological conditions, in addition to the resident …

Non-alcoholic fatty liver disease (NAFLD) has emerged pandemically across the globe and
particularly affects patients with obesity and type 2 diabetes. NAFLD is a complex systemic …

Metabolic (dysfunction)-associated fatty liver disease (MAFLD) affects up to a third of the
global population; its burden has grown in parallel with rising rates of type 2 diabetes …

Executive summary Liver diseases have become a major health threat across Europe, and
the face of European hepatology is changing due to the cure of viral hepatitis C and the …